April 4, 2013 /PRNewswire/ --
Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today that it will begin the market launch of its proprietary Sublative technology for the removal or modification of the appearance of acne scars. The acne scar treatment is available on all of the Syneron Sublative compatible systems, which includes elōs Plus™, eTwo™ and eMatrix™.
Acne is the most common skin disorder in
the United States
, affecting 40 to 50 million Americans. By mid-teens, more than 40 percent of adolescents have acne or acne scarring, which requires treatment by a dermatologist.
Syneron's Sublative technology is the only bi-polar fractional radiofrequency (RF) energy device proven to effectively treat acne scars. Due to its unique design, energy can now be delivered beneath the surface of the skin to maximize collagen production while preserving the top layer of the skin intact. This means patients benefit from significant results without the down time or potential complications of more aggressive treatments.
"As an early adopter of the Sublative technology it's been a real delight to have been at the forefront of this revolutionary technology and see it evolve to serve as my staple treatment for my acne scar patients," said
, M.D., board certified dermatologist and Medical Director at the Gold Skin Care Center in
. "While there are nonsurgical to surgical methods to treating a wide range of superficial to defused acne scars, my go-to-treatment is Sublative due to its exceptional results, minimal downtime and unmatched safety profile."
In conjunction with the new acne scar treatment, Syneron will introduce "Skinhibitions" - a new focused consumer marketing campaign based on market research the company completed which showed that a majority of women were interested in more efficacious skin procedures but were inhibited by fear of pain, significant down time, side effects and high cost. In an online survey commissioned by Syneron, 22 percent of adults 18 years and older considered acne scars to be an issue that they would like to do something about. Of the respondents that have acne scars, 77 percent responded that they would like to seek a treatment but are inhibited by high costs, pain, downtime and lack of results. Importantly, this survey also indicated more than half of these patients would seek more information about Sublative technology.
Stock quotes in this article: